androgen receptor degrader-1 — TargetMol Chemicals

Cat No.	Product Name	Targets
T80633	Androgen receptor degrader-1	Androgen Receptor
	Androgen Receptor Degrader-1 (Compound 18) is a potent agent for androgen receptor degradation, applicable in cancer research [1].	Androgen Receptor
T13273	UT-34	Androgen Receptor
	UT-34 is a selective and orally active antagonist of second-generation pan-androgen receptor (AR) and degrader(IC50s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively), and has anti-prost...	Androgen Receptor
T80647	Androgen receptor degrader-2	Androgen Receptor
	Androgen Receptor Degrader-2 (Compound 9) is a potent degrader of androgen receptors, with potential application in cancer research [1].	Androgen Receptor
T79891	Androgen receptor degrader-3	Androgen Receptor
	Androgen Receptor Degrader-3 (ARD-3) is a compound that inhibits androgen receptor signaling and promotes the degradation of the receptor, with potential applications in prostate cancer research [1].	Androgen Receptor
T18596	PROTAC AR Degrader-4	Others
	PROTAC AR Degrader-4 comprises a cIAP1 ligand binding group, a linker and an androgen receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-g...	Others
T74520	TD-802
	TD-802 (Compound 33c), an androgen receptor (AR) PROTAC degrader, exhibits strong microsomal stability and demonstrates potent antitumor efficacy in vivo, making it suitable for research on metastatic castration-resistan...
T73726	PROTAC AR Degrader-4 TFA
	PROTAC AR Degrader-4, an Androgen Receptor (AR) degrader, incorporates an IAP ligand binding group, a linker, and an AR binding group. It represents a class of degradation inducers known as specific and non-genetic IAP-d...
T18873	VHL Ligand-Linker Conjugates 17	Others
	VHL Ligand-Linker Conjugates 17 are chemical compounds that consist of a VHL ligand specialized for the E3 ubiquitin ligase, as well as a PROTAC linker. These conjugates are utilized in the synthesis of various PROTACs, ...	Others
T14318	ARCC-4	Others
	ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide and it is a low-nanomolar androgen receptor (AR) degrader based on PROTAC, with a DC50 of 5 nM. ARCC-4 effectively...	Others
T13552	ARD-266	Others
	ARD-266 is a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces the degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines (DC50s...	Others
T74410	PROTAC AR-V7 degrader-1
	PROTAC AR-V7 degrader-1 (Compound 6) is an orally bioavailable, potent, and selective degrader targeting the androgen receptor (AR) variant V7, achieving degradation with a DC50 of 0.32 µM by directing the VHL E3 ligase ...
T74745	A031
	A031, a potent PROTAC androgen receptor (AR) degrader, demonstrates significant efficacy with an IC50 value under 0.25 μM for AR protein degradation. Additionally, it exhibits an inhibitory impact on tumor growth in zebr...
T79725	ARD-1676	Androgen Receptor
	ARD-1676 is an orally administered androgen receptor (AR) PROTAC degrader that combines an AR ligand with a cereblon ligand. It demonstrates AR-degrading activity both in vitro and in vivo, and effectively inhibits VCaP ...	Androgen Receptor
T78922	ARD-2051	PROTACs
	ARD-2051 is a potent, orally active proteolysis-targeting chimera degrader of the androgen receptor (AR), exhibiting DC50 values of 0.6 nM in degrading AR protein within LNCaP and VCaP prostate cancer cell lines. It hold...	PROTACs
T79519	YXG-158	Androgen Receptor
	YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1.28 μM and CYP17A1 inhibition with an IC50 of 100 nM. It is ...	Androgen Receptor
T13958	VHL Ligand 8	Others
	VHL Ligand 8, a VHL ligand essential for synthesizing ARD-266, acts as a highly potent VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. It efficiently facilitates the degradation of AR protein in AR-positive p...	Others